2nd Quarter - Report

GENENTECH, INC for GENENTECH INC

Firm
Client
Income
—
Expenses
$1,800,100
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Issues relating to U.S. trade policy

LobbyistCovered position, as disclosed
ELI KOGAN Assistant Director

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Issues relating to corporate tax reform including the R&D tax credit and taxation of foreign-owned corporations; Issues related to tax reform and tax extenders.

LobbyistCovered position, as disclosed
DAVID B BURT Director
ELI KOGAN Assistant Director

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Copyright/Patent/Trademark CPT

general lobbying; MMM: Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; Issues related to 340B;

LobbyistCovered position, as disclosed
ELI KOGAN Assistant Director

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Patent Terms, Pandemic Preparedness, Tamiflu Stockpile, Appropriations; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics, comparative effectivness research, and FDA approval of follow-on biologics; Pubic law 111-152, the Health Care and Education Reconcilation Act of 2010 - Implementation issues related Medicare and Medicaid payment for biotherapeutics, the 340B program, and the Medicare drug benefit; Meetings with Administration and congressional staff on coverage/payment issues related to cancer biotherapeutics, 340B program; Meetings with Administration staff concerning the President's precision medicine initiative; Ongoing issues related to the implementation of the Affordable Care Act of 2010; Drug pricing under 340B program; issues related to H.R. 6, the 21st Century CURES Act; 21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee); issues concerning implementation of Patient Protection and Affordable Care Act; Drug pricing under 340B program;

LobbyistCovered position, as disclosed
DAVID B BURT Director
ANNA GRIFFIN Sr. Director
KATHERINE RAAB Director

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 6 (114th)

Medicare/Medicaid MMM

Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicaid reimbursement for biotherapeutics; HR 1470 and S.810, the SGR Repeal and Medicare Provider Payment Modernization Act of 2015 - Medicare physician payment reform, payment for Part B drugs; Public Law 114-110, the Medicare Access and CHIP Reauthorization Act - Medicare physician payment reform and CHIP extension, payment for PART B drugs; Concerns regarding Medicare policies for Part B drugs. Issues related to the 340B Drug discount program; Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; Issues related to 340B;

LobbyistCovered position, as disclosed
DAVID B BURT Director
ANNA GRIFFIN Sr. Director

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 810 (114th), H.R. 1470 (114th)

Budget/Appropriations BUD

Issues to theFY 2015 Department of Labor, Health and Human Services and Education , and Related Agencies Appropriations and issue related to S. Con. Res. 11 and H. Con Res 27; Issues related to FDA & HHS program funding, FY16 Labor Health and Human Services, and Education, and Related Agencies, and FY 16 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Bills;

LobbyistCovered position, as disclosed
ANNA GRIFFIN Sr. Director
ELI KOGAN Assistant Director

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S.Con.Res. 11 (114th), H.Con.Res. 27 (114th)

Pharmacy PHA

Public Law 111-148, the Patient Protection and Affordable Care Act 0 Implementation issues related to FDA approval of follow on biologics and length of data exclusivity period, 340B drug pricing program, structure of the Medicare prescription drug benefit.; Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid reimbursement, fees assessed on the pharmaceutical industry, design and structure of the Medicare prescription; General issues and congressional oversight related to FDA approval and CMS coverage decisions regarding Avastin and Lucentis.; Held discussions with Administration staff about 340B program requirements on participating pharmaceutical manufacturers., Held preliminary discussion with Administration staff on anti-viral drugs in the strategic national stockpile.

LobbyistCovered position, as disclosed
DAVID B BURT Director
ELI KOGAN Assistant Director
KATHERINE RAAB Director

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.